HALOZYME THERAPEUTICS, INC. - 8-K Filing
Halozyme Therapeutics issued $1.5B in convertible senior notes due 2033 with a coupon rate of 1.5%, used proceeds to repurchase existing debt and for general corporate purposes. (Items: 1.01 Entry into a Material Definitive Agreement, 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, 3.02 Unregistered Sales of Equity Securities The information set forth in Item 1, 9.01 Financial Statements and Exhibits)
Tickers: $HALO